Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
PD-L1 Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2024
PD-L1 Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2024
Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) is a protein that in humans is encoded by the CD274 gene. Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the adaptive arm of immune systems during particular events such as pregnancy, tissue allografts, autoimmune disease, and other disease states such as hepatitis. The mechanism of action (MOA) of PD-L1 Inhibitor is by binding to PD-L1, the inhibitors prevent its interaction with PD-1, and the binding of PD-L1 to PD-1 receptor on immune cells, such as T cells, inhibits the immune response and promotes immune evasion by cancer cells. PD-L1 inhibitors disrupt this interaction, preventing the inhibitory signal that PD-L1 delivers to PD-1. As a result, the immune response against cancer cells is reactivated. PD-L1 inhibitors are used for the treatment of lymphoma, leukemia, sarcoma, hematologic diseases, glioblastoma, lung diseases, gastrointestinal diseases, colorectal neoplasms, etc. Increased prevalence of sarcoma and lymphoma are the key drivers for the PD-L1 Inhibitor market. For instance, according to the World Health Organization 2023, non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. Launch of newer products by the market players could seek opportunities that influence extensive research and development in PD-L1 inhibitors. For instance, AstraZeneca’s Imfinzi (Durvalumab) is launched for the treatment of small cell lung cancer. Moreover, the development of novel molecules by many market players is coming up to overcome challenges in therapy. For instance, Sorrento’s Socazolimab (STI-A1014) for the indication of lung cancer is under the various stages of clinical studies.
Key Market Developments:
Approved Drug Molecules and Brand Names for PD-L1 Inhibitor:
Drugs under the Pipeline for PD-L1 Inhibitor:
Clinical Activity and Developments of PD-L1 Inhibitor:
Till July 2023, more than 80 companies have approximately 103 molecules targeting the 90 diseases. For these molecules, more than 1600 clinical trials are being conducted and majority are in phase-2, and phase-3 clinical trials by players across the globe. For instance,
|
Molecule Name |
Number of Studies |
|
Zimberelimab (AB122) |
48 |
|
APL-502 |
45 |
|
Adebrelimab (SHR-1316) |
30 |
|
Retlirafusp Alfa (SHR-1701) |
29 |
|
Ezabenlimab (BI 754091) |
28 |
The molecules such as Tecentriq (Atezolizumab) were developed by Roche for the treatment of metastatic NSCLC with high PD-L1 expression with no EGFR or ALK genomic tumor aberrations, unresectable or metastatic hepatocellular carcinoma in combination with Avastin (Bevacizumab), in combination with Cobimetinib (Cotellic) and Vemurafenib (Zelboraf) for the treatment of patients with advanced BRAF V600 mutation-positive melanoma. Moreover, Merck’s Bavencio (Avelumab) for the treatment of Merkel cell carcinoma, in combination with Inlyta (axitinib) for the first-line treatment of advanced renal cell carcinoma and locally advanced or metastatic urothelial carcinoma.
The total global annual sale of Roche’s Tecentriq (Atezolizumab) was US$ 4,066.81 million in FY2022. With a growth of 29% CAGR between 2019 to 2022. Tecentriq was first approved in 2016 and is sold globally including in the US, the UK, France, Germany, and Japan by F. Hoffmann-La Roche Ltd. Increase incidence of Lymphoma, lung cancer, and other cancers Seems to create the opportunity for the future and burgeon the growth of the PD-L1 Inhibitor market. For instance, according to Cancer Research UK, there are around 48,500 new lung cancer cases in the UK every year and there could be around 66,200 new cases of lung cancer every year in the UK by 2038-2040; this is expected to create lucrative opportunity for PD-L1 Inhibitor market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Tecentriq (Atezolizumab), Imfinzi (Durvalumab), Bavencio (Avelumab) are the few FDA-approved PD-L1 Inhibitor.
Total global annual sale of Roche’s Tecentriq (Atezolizumab) was US$ 4,066.81 million in FY2022.
Roche, AstraZeneca, EMD Serono, Incyte, etc are a few leading market players in PD-L1 Inhibitor.
Major Indications for PD-L1 Inhibitors are lymphoma, leukemia, sarcoma, hematologic diseases, glioblastoma, lungs diseases, gastrointestinal diseases, colorectal neoplasms, etc.
There are more than 60 molecules that are in the Phase-1, Phase-2, and Phase-3 clinical development.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.